Scarica l'app Stockscreener
56.81
2.14%
1.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results | SRPT Stock News - GuruFocus
Sarepta Therapeutics To Announce First Quarter 2025 Financial Results - marketscreener.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results - Business Wire
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Insider Monkey
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - Investor's Business Daily
11 Most Promising Long-Term Stocks According to Analysts - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Piper Sandler Cuts Price Target for Sarepta (SRPT) Amid Elevidys Sales Concerns | SRPT Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Thera - NatLawReview.com
Sarepta (SRPT) Price Target Lowered by BofA Ahead of Q1 Earnings | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Sarepta Therapeutics’ (SRPT) Neutral Rating Reiterated at HC Wainwright - Defense World
Cancer Retains Top Spots In Alliance Deal Volume, Value - insights.citeline.com
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating - marketscreener.com
FDA OKs trial of SRP-9005 gene therapy for LGMD type 2C - Muscular Dystrophy News
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week - Yahoo Finance
Lobbying Update: $320,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements - TipRanks
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies - Zacks Investment Research
Sarepta (SRPT) Advances Gene Therapy Trials for Muscular Dystrop - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Announces Pipeline Progress For Multiple Limb-Girdle Muscular Dystrophy Programs - marketscreener.com
Sarepta Therapeutics Announces Pipeline Progress for Multiple Li - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials - Investing.com
Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - StreetInsider
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - itemonline.com
Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan
Trump health policy uncertainty sends biotech sector into deeper slump - MarketScreener
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by O Shaughnessy Asset Management LLC - Defense World
Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00 - Defense World
Wells Fargo Initiates Coverage of Sarepta Therapeutics (BMV:SRPT) with Overweight Recommendation - Nasdaq
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) wi - GuruFocus
Sarepta stock wins bullish view at Wells Fargo (SRPT:NASDAQ) - Seeking Alpha
Sarepta (SRPT) Price Target Cut by Morgan Stanley Ahead of Earni - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Wells Fargo Starts Sarepta (SRPT) with Overweight Rating, Targets $115 | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - Defense World
Sarepta Therapeutics (SRPT) Sees Price Target Reduction by Gugge - GuruFocus
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Q1 EPS Estimate for Sarepta Therapeutics Reduced by Analyst - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025 - CGTLive®
Independent DMC Concludes that Risk-Benefit Ratio for Sarepta’s DMD Gene Therapy Elevidys Remains Favorable - CGTLive®
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Business Wire
Sarepta (SRPT) Shares Fall Over 6% Following EMA Clinical Hold - GuruFocus
Sarepta (SRPT) Seeks Continuation of Elevidys Trials Amid Safety Review - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Financial Content
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Can Solid Biosciences Challenge Sarepta in the DMD Market? - MarketBeat
1.75%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):